Hydrocortisone butyrate is a medium-potency topical corticosteroid used primarily for inflammatory skin conditions like atopic dermatitis, eczema, and certain forms of psoriasis. It sits in an interesting middle ground: potent enough to control moderate flares, yet mild enough that dermatologists often reach for it when stronger steroids feel risky, particularly on sensitive skin or in children. The “butyrate” part of the name isn’t just a chemical footnote; it’s the reason the drug works meaningfully better than plain hydrocortisone, even though both share the same parent molecule.
What the Butyrate Ester Actually Does
Hydrocortisone on its own is a weak topical steroid. Attaching a butyrate group (a short fatty-acid chain) to the hydrocortisone molecule at a specific position changes two things that matter clinically: it makes the drug penetrate skin more easily, and it makes the drug bind to glucocorticoid receptors with considerably more grip. In receptor-binding studies, esterification with butyrate at the 17-alpha position increased the molecule’s affinity for the glucocorticoid receptor roughly twelve-fold compared with unmodified cortisol.1PubMed. Relative affinity of 17 alpha- and/or 21-esters and 17 alpha, 21-diesters of cortisol for a glucocorticoid receptor from rat thymocytes A separate study looking at the related diester hydrocortisone 17-butyrate 21-propionate found that the esterified form bound the receptor along a single high-affinity binding curve, and that the increased affinity was driven by a slower rate of dissociation from the receptor.2Biochemical Pharmacology. Enhancement of affinity to receptors in the esterified glucocorticoid, hydrocortisone 17-butyrate 21-propionate (HBP), in the rat liver
In plain terms, the butyrate group helps the drug latch onto its target inside skin cells and stay latched on longer. Once bound, it suppresses the inflammatory cascade the same way all corticosteroids do, dialing down the immune signaling that causes redness, swelling, and itch. The practical result is a product that is far more effective than over-the-counter hydrocortisone 1% cream but doesn’t carry the same risk profile as the truly potent steroids like betamethasone valerate or clobetasol propionate.
Where It Fits on the Potency Ladder
Topical corticosteroids are ranked by potency into seven classes in the U.S. system (Class 1 being the strongest, Class 7 the weakest) or four tiers in the European/British system (mild, moderate, potent, very potent). Hydrocortisone butyrate 0.1% is typically classified as a medium-potency steroid, landing around Class 5 in the American system. That puts it above mild agents like hydrocortisone acetate 1% and below potent agents like betamethasone valerate 0.1%. Some classification systems place it at the lower end of the “potent” category depending on the vehicle. The vehicle matters: the same 0.1% concentration in an ointment base generally delivers more drug into the skin than a cream or lotion, which can shift its effective potency.
This middle positioning is a big part of why dermatologists like it. For conditions that need more than a mild steroid but don’t warrant the heavier side-effect burden of a potent one, hydrocortisone butyrate fills the gap nicely.
Conditions It Treats
The primary indication is atopic dermatitis (eczema), and much of the clinical evidence clusters around this use. In head-to-head comparisons with other mid-range steroids, hydrocortisone butyrate 0.1% cream reduced itch scores in atopic dermatitis patients from maximum severity down to near zero over two weeks, performing comparably to other steroids in the same class.3PubMed Central. The effects of treatment on itch in atopic dermatitis A randomized trial comparing it with the experimental agent cipamfylline found that hydrocortisone 17-butyrate significantly reduced total severity scores in adult atopic dermatitis.4British Journal of Dermatology. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17‐butyrate cream for the treatment of atopic dermatitis
Beyond eczema, clinicians prescribe it for contact dermatitis, seborrheic dermatitis, psoriasis in sensitive areas (scalp, flexures), and various other inflammatory dermatoses. It’s also used off-label for vulvar lichen sclerosus and other genital skin conditions where a medium-potency steroid is appropriate.
Use in Children
Pediatric use is one of the areas where hydrocortisone butyrate has been studied most carefully. A controlled trial of the 0.1% lotion in children as young as three months demonstrated both safety and efficacy for mild to moderate atopic dermatitis, with physician assessments showing a significant treatment effect compared to vehicle alone.5Journal of Drugs in Dermatology. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects A separate study of the lipocream formulation in pediatric patients down to three months of age found it more effective than vehicle with no serious adverse events reported during treatment for up to one month.6PubMed. Hydrocortisone butyrate 0.1% lipocream in pediatric patients atopic dermatitis
Parents often worry about steroid absorption in children, particularly because kids have a higher body-surface-area-to-weight ratio, which means proportionally more drug can get into the bloodstream. The evidence here is reassuring for hydrocortisone butyrate specifically. A study of children aged five to twelve who were treated three times daily (a heavier-than-usual dosing schedule) with a lipid-rich hydrocortisone butyrate 0.1% formulation for four weeks found no evidence of adrenal suppression on stimulation testing.7PubMed. Evaluation of adrenal suppression of a lipid enhanced, topical emollient cream formulation of hydrocortisone butyrate 0.1% in treating children with atopic dermatitis The researchers did note, however, that these results may not apply to children under five, where body proportions differ more significantly.
For context, a meta-analysis looking across all potency classes of topical corticosteroids in children found that HPA axis suppression occurred in about 4% of pediatric patients overall, with rates climbing from roughly 2% for low-potency steroids up to about 7% for high-potency ones.8PubMed. Evaluation of Hypothalamic-Pituitary-Adrenal Axis Suppression following Cutaneous Use of Topical Corticosteroids in Children: A Meta-Analysis Medium-potency products like hydrocortisone butyrate fell in between, at about 3%. These numbers are low, and most cases of suppression in studies were mild and reversible, but they do support the general advice to use the lowest effective potency for the shortest reasonable duration.
Skin Thinning and Local Side Effects
The side effect people fear most from topical steroids is skin thinning (atrophy). This fear is warranted to a degree but often overstated for medium-potency products used appropriately. All corticosteroids can thin the skin with prolonged use, and the risk scales with potency, duration, and the vulnerability of the site being treated.
A controlled study comparing hydrocortisone butyrate to stronger steroids under occlusion (the worst-case scenario for absorption) found that skin thickness decreased significantly with all the corticosteroids tested, including hydrocortisone butyrate 0.1%, betamethasone valerate 0.1%, and clobetasol propionate 0.05%. However, all of these were applied under occlusive dressings for four weeks straight, which is far more aggressive than typical clinical use.9Dermatologica. Domoprednate (Stermonid®), a Topical D-Homocorticosteroid, Skin Atrophy and Telangiectasia
A more clinically relevant study looked at what happens to facial skin when hydrocortisone 1% cream (a mild steroid, weaker than hydrocortisone butyrate) is applied twice daily for just two weeks. Even at that low potency and short duration, researchers detected a statistically significant decrease in epidermal thickness using optical coherence tomography. The encouraging finding was that thickness returned to baseline within four weeks of stopping treatment, and no dermal thinning or visible blood vessel changes were observed.10PubMed. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography The takeaway is that short courses, even on the face, tend to cause only transient changes that reverse once you stop. Problems accumulate when use becomes continuous over months.
The Face and Other Sensitive Sites
Facial skin is thinner and absorbs topical steroids more readily than skin on the trunk or limbs. This makes the face, eyelids, groin, and skin folds higher-risk areas for steroid side effects. Hydrocortisone butyrate has been used on the face, and early reports suggested it might be suitable for longer-term facial use. One preliminary study noted that rebound eruption occurred in about 10% of patients after discontinuation on facial lesions, which the authors interpreted as a signal that caution was still needed.11PubMed. Hydrocortisone 17-butyrate: a new topical corticosteroid preliminary report
A more sobering observation came from a case series that identified seven patients who developed perioral dermatitis associated specifically with the use of hydrocortisone butyrate on the face. The authors concluded that this steroid could no longer be recommended “unreservedly” for facial use.12PubMed. Perioral dermatitis Perioral dermatitis is a frustrating condition in which a rash develops around the mouth, often triggered or worsened by topical steroids. It creates a vicious cycle: the steroid temporarily suppresses the rash, so you keep applying it, but the steroid is actually sustaining or worsening the underlying condition.
Current practice reflects these findings. Most dermatologists will prescribe hydrocortisone butyrate for short bursts on the face (a week or two during a flare) but prefer non-steroidal alternatives like tacrolimus or pimecrolimus for ongoing maintenance on facial skin.
How It Compares to Tacrolimus and Pimecrolimus
Calcineurin inhibitors (tacrolimus ointment and pimecrolimus cream) are the main non-steroidal prescription alternatives for eczema. They don’t cause skin thinning, which makes them attractive for long-term use on the face and other sensitive areas. But how do they stack up against hydrocortisone butyrate in terms of raw effectiveness?
A direct comparison trial in adults with moderate to severe atopic dermatitis found that 0.1% tacrolimus ointment and 0.1% hydrocortisone butyrate ointment performed similarly, with no statistically significant difference in their primary efficacy measure. The lower-strength 0.03% tacrolimus was significantly less effective than both. Patients in the tacrolimus groups, however, reported more skin burning and itching at the application site.13Journal of Allergy and Clinical Immunology. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis
A meta-analysis of calcineurin inhibitors for atopic dermatitis added more texture. It found that 0.1% tacrolimus was as effective as potent topical corticosteroids at three weeks and actually outperformed a combination regimen of hydrocortisone butyrate on the trunk plus mild hydrocortisone acetate on the face at twelve weeks. But the lower-strength 0.03% tacrolimus was less effective than hydrocortisone butyrate 0.1% alone.14PubMed Central. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials An immunohistochemical study showed that tacrolimus produced broader suppression of inflammatory markers, including a greater reduction in lymphocytes, eosinophils, and most cytokines compared with hydrocortisone butyrate.15British Journal of Dermatology. The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study
The practical upshot: for short-term flare control on most body sites, hydrocortisone butyrate and tacrolimus 0.1% are roughly equivalent. For long-term management, especially on the face and around the eyes, tacrolimus and pimecrolimus have the advantage of not thinning skin. The tradeoff is that calcineurin inhibitors sting or burn on application, particularly in the first few days, which can be a dealbreaker for some patients.
How Often You Need to Apply It
Most prescriptions call for twice-daily application, and that’s how hydrocortisone butyrate has been used in the majority of clinical trials. But there’s a real question about whether once daily would work just as well. A systematic review of topical corticosteroid dosing frequency for eczema found that for potent steroids, studies showed little difference between once-daily and more frequent application.16British Journal of Dermatology. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once‐daily vs. more frequent use No trials specifically on mild-potency products were identified, and the evidence base overall was described as sparse. Still, the direction of the evidence suggests that once-daily use of medium-to-potent steroids may be adequate for many patients, which would reduce total steroid exposure and improve adherence.
In practice, some dermatologists already prescribe once-daily application for maintenance and step up to twice daily only during active flares. The formulation also matters here. Ointment bases tend to have longer skin contact and slower drug release, which may make once-daily application more feasible than it would be with a lotion that absorbs and dries quickly.
Contact Allergy to Hydrocortisone Butyrate Itself
This is a genuinely surprising phenomenon that most patients don’t know about: you can develop a contact allergy to the very corticosteroid you’re using to treat your skin. It’s uncommon but well-documented. The irony is that because the steroid partially suppresses the allergic reaction it’s causing, the allergy can masquerade as a treatment failure or a worsening of the original condition.
Hydrocortisone butyrate occupies a unique role in diagnosing corticosteroid allergy. Researchers found that it cross-reacts with most other corticosteroids that cause contact allergies, making it a useful screening agent. In a large patch-testing study, 0.5% of the general dermatology population showed definite allergic reactions to corticosteroids when screened, and among patients confirmed to have corticosteroid allergy, 33 out of 34 reacted to hydrocortisone 17-butyrate on patch testing.17PubMed. Detection of contact hypersensitivity to topical corticosteroids with hydrocortisone-17-butyrate The authors recommended including hydrocortisone butyrate 1% in ethanol in standard patch-test series to improve detection.
If your eczema is getting worse despite using a topical steroid, or if you notice irritation in areas where you apply it that doesn’t match your usual disease pattern, it’s worth asking your dermatologist about patch testing for steroid allergy. Switching to a structurally unrelated corticosteroid or to a non-steroidal alternative often resolves the problem.
Steroid Phobia and Treatment Adherence
One of the largest practical barriers to effective treatment isn’t the drug itself but fear of the drug. “Topical corticosteroid phobia” is a recognized phenomenon in which patients (or parents of pediatric patients) underuse prescribed steroids because of anxiety about side effects, often based on exaggerated information from the internet or well-meaning but inaccurate advice. Undertreating eczema carries its own harms: persistent itch, sleep disruption, skin infections, and scarring from chronic scratching.
A prospective study of women with vulvar lichen sclerosus examined whether corticosteroid phobia affected treatment adherence and outcomes. About 82% of patients adhered to the prescribed steroid regimen, and among those who did, treatment was highly effective at relieving symptoms and improving clinical signs. The study found that the degree of corticosteroid phobia did not significantly predict whether patients adhered to treatment or how well it worked.18PubMed. Effect of Corticosteroid Phobia on Treatment Adherence and Outcome in Women With Lichen Sclerosus: A Prospective Study That’s somewhat reassuring, though the study population was relatively small and motivated by the severity of their condition. In milder disease, where the stakes feel lower, phobia likely plays a bigger role in non-adherence.
The best antidote to steroid phobia is specific information. Knowing that hydrocortisone butyrate is a medium-potency agent, not a super-potent one; that short courses cause only reversible skin changes; that systemic absorption at typical doses is minimal; and that untreated inflammation also damages the skin can help patients use the medication as prescribed rather than rationing it out of fear.
Available Formulations
Hydrocortisone butyrate 0.1% comes in several vehicles, and the choice between them is more than cosmetic preference.
- Ointment: The greasiest option, best for dry, thickened, or lichenified skin. Ointments deliver more drug into the skin and provide an occlusive barrier that traps moisture. They’re poorly tolerated on hairy areas and in skin folds where moisture already accumulates.
- Cream: The most commonly prescribed form, suitable for most body sites and skin types. Creams spread easily and are cosmetically acceptable, though they contain more excipients (preservatives, emulsifiers) that can occasionally irritate sensitive skin.
- Lipocream: A lipid-enriched cream formulation designed to double as a moisturizer. This is the form studied in several pediatric trials and tends to be well-tolerated on dry, eczematous skin.
- Lotion: The thinnest vehicle, useful for hairy areas like the scalp or for covering large body surface areas without the heaviness of a cream.
- Solution: Primarily used on the scalp, where creams and ointments are impractical.
The vehicle affects how much drug actually gets into the skin. An ointment-based formulation will generally deliver a higher effective dose than a lotion at the same concentration, which is why some potency classification systems list the same drug in different potency tiers depending on vehicle. Your dermatologist’s choice of vehicle reflects both the location being treated and the severity of the condition, not just patient preference.